Literature DB >> 30393601

A new era of treating advanced lung cancer is upon us.

Glen J Weiss1.   

Abstract

Entities:  

Year:  2018        PMID： 30393601      PMCID： PMC6193912          DOI： 10.21037/tlcr.2018.07.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Bishal Gyawali; Akiko Ota; Yuichi Ando
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

2.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Authors:  Sarah B Goldberg; Azeet Narayan; Adam J Kole; Roy H Decker; Jimmitti Teysir; Nicholas J Carriero; Angela Lee; Roxanne Nemati; Sameer K Nath; Shrikant M Mane; Yanhong Deng; Nitin Sukumar; Daniel Zelterman; Daniel J Boffa; Katerina Politi; Scott N Gettinger; Lynn D Wilson; Roy S Herbst; Abhijit A Patel
Journal:  Clin Cancer Res       Date:  2018-01-12       Impact factor: 12.531

8.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Authors:  L Derosa; M D Hellmann; M Spaziano; D Halpenny; M Fidelle; H Rizvi; N Long; A J Plodkowski; K C Arbour; J E Chaft; J A Rouche; L Zitvogel; G Zalcman; L Albiges; B Escudier; B Routy
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more
  1 in total

1.  Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.

Authors:  Xiaohui Zeng; Xiaomin Wan; Liubao Peng; Ye Peng; Fang Ma; Qiao Liu; Chongqing Tan
Journal:  BMJ Open       Date:  2019-12-11       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.